Hydrochloric Acid → 5-(5-Ethyl-1H-pyrazol-4-yl)-N-(4-morpholinophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine
反応式
[CH2:1]([C:3]1[N:7](C2CCCCO2)[N:6]=[CH:5][C:4]=1[C:14]1[N:19]2[N:20]=[CH:21][N:22]=[C:18]2[C:17]([NH:23][C:24]2[CH:29]=[CH:28][C:27]([N:30]3[CH2:35][CH2:34][O:33][CH2:32][CH2:31]3)=[CH:26][CH:25]=2)=[N:16][CH:15]=1)[CH3:2].C(C1C(C2N3N=CN=C3C(NC3C=CC(N4CCOCC4)=CC=3)=NC=2)=CN(C2CCCCO2)N=1)C.Cl>CO>[CH2:1]([C:3]1[NH:7][N:6]=[CH:5][C:4]=1[C:14]1[N:19]2[N:20]=[CH:21][N:22]=[C:18]2[C:17]([NH:23][C:24]2[CH:25]=[CH:26][C:27]([N:30]3[CH2:31][CH2:32][O:33][CH2:34][CH2:35]3)=[CH:28][CH:29]=2)=[N:16][CH:15]=1)[CH3:2]参加物
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
A solution of {5-[5-ethyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-[1,2,4]triazolo[1,5-a]pyrazin-8-yl}-(4-morpholin-4-yl-phenyl)-amine and {5-[3-ethyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-[1,2,4]triazolo[1,5-a]pyrazin-8-yl}-(4-morpholin-4-yl-phenyl)-amine (40 mg, 0.077 mmol) and conc. HCl (0.3 mL) in MeOH (10 mL) is stirred at room temperature for 5 hours. After removing the solvent, the solid residue is partitioned between ethyl acetate and sat. NaHCO3. The undissolved solid is collected by filtration, washed with water, diethyl ether and petroleum ether and dried to afford the title compound (5 mg, 17%). Conversion into the mesylate salt using 0.1M methanesulfonic acid (0.128 mL) affords the title compound (5.6 mg, 89%) as a solid.
後処理
- customAfter removing the solvent
- customthe solid residue is partitioned between ethyl acetate and sat. NaHCO3
- filtrationThe undissolved solid is collected by filtration
- washwashed with water, diethyl ether and petroleum ether
- customdried
出典と根拠
- ORDレコード
- ord-bec95c032eb84b4ca0472d157d283fe2
- 出典データセット
- uspto-grants-2009_03
- 特許番号
- US07501411B2
反応ノート
読み込み中…